Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Alpha and Omega Semiconductor, LogicBio, PaySign, and XP and Encourages Investors to Contact the Firm NEW YORK, April 01, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cronos Group, Gulfport Energy, Alpha and Omega Semiconductor, and LogicBio Therapeutics and Encourages Investors to Contact the Firm NEW YORK, March 25, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf...

LogicBio Therapeutics Announces Submission of Investigational New Drug Application (IND) for LB-001 for Methylmalonic Acidemia (MMA) and Highlights Key Corporate Milestones – Filed IND for lead GeneRide™ candidate LB-001 in pediatric MMA patients –– Phase 1/2 trial initiation planned for H1 2020, with preliminary data in H2 2020 –– Established research collaboration with...

LogicBio Therapeutics Announces Collaboration with Takeda to Develop New Genome Editing Candidate LB-301 for the Treatment of Crigler-Najjar Syndrome – LB-301 is a recombinant AAV vector with a UGT1A1 gene leveraging GeneRide™ genome editing platform for the treatment of Crigler-Najjar syndrome – – The collaboration agreement grants Takeda an...